21shares_B_Logotype_Marigold_Digital.png
21Shares Announces Fee Reduction for Flagship ETPs, HODLX and BOLD
September 24, 2024 03:00 ET | 21Shares
ZURICH, 24 September 2024 – 21Shares AG ("21Shares"), one of the world's largest issuers of cryptocurrency exchange traded products (ETPs) and a subsidiary of 21.co, is pleased to announce a...
Basilea-Logo.jpg
Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis
September 24, 2024 01:15 ET | Basilea Pharmaceutica AG, Allschwil
Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an...
Basilea-Logo.jpg
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
September 24, 2024 01:15 ET | Basilea Pharmaceutica AG, Allschwil
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
Santhera gibt Annahm
Santhera gibt Annahme des Zulassungsantrags für AGAMREE® (Vamorolon) bei Duchenne-Muskeldystrophie durch Swissmedic bekannt
September 24, 2024 01:00 ET | Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, 24. September 2024 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Schweizerische Heilmittelinstitut Swissmedic das Zulassungsgesuch (marketing authorization...
Santhera Announces A
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
September 24, 2024 01:00 ET | Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing...
roche-logo-blue.png
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
September 24, 2024 01:00 ET | F. Hoffmann-La Roche Ltd
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers...
Schw.Tech_RGB.jpg
Schweiter Technologies Innovation & Capital Markets Day 2024
September 24, 2024 00:00 ET | Schweiter Technologies
Ad hoc-Mitteilung gemäss Art. 53 des Kotierungsreglements der SIX Schweiter Technologies Innovation & Capital Markets Day 2024 Profitable growth with sharpened strategy Sharpened strategic...
WISeKey Logo.png
WISeKey Announces OISTE’s Participation at the Summit of the Future
September 23, 2024 17:41 ET | Wisekey International Holding Ltd.
WISeKey Announces OISTE’s Participation at the Summit of the Future New York, New York - September 23, 2024: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY),...
21shares_B_Logotype_Marigold_Digital.png
21.co Integrates Chainlink Proof of Reserve To Increase Transparency of its Wrapped Bitcoin (21BTC) on Solana and Ethereum
September 23, 2024 12:00 ET | 21Shares
ZURICH, 23 September 2024 – 21.co, the parent company of 21Shares – one of the world’s largest issuers of crypto exchange traded products (ETPs), today announced the integration of the...
roche-logo-blue.png
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
September 23, 2024 01:00 ET | F. Hoffmann-La Roche Ltd
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in...